
Photo from Ravi Madan/X
Jul 11, 2024, 12:34
Ravi Madan: Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing
Ravi Madan, Clinical researcher focused on Prostate Cancer at National Cancer Institute, shared a post on X: .
“Now online. European Urology Oncology: Enzalutamide Monotherapy in EMBARK BCR Prostate Cancer Should Be Practice-changing, and Existing Data Suggest How to Mitigate Toxicity.”
Visit the article website.
Source: Ravi Madan/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 22, 2025, 10:56
Mar 22, 2025, 10:52
Mar 22, 2025, 10:49
Mar 22, 2025, 10:34
Mar 22, 2025, 09:58
Mar 22, 2025, 09:11